As the most abundant secretory product of adipocytes, the bioactive protein adiponectin has been a major focus of efforts to define the endocrine functions of adipose tissue and their role in obesity-associated disorders. 1 Unlike other adipokines, adiponectin is inversely related to adiposity, and demonstrates insulin-sensitizing and anti-atherogenic properties in the laboratory. 1 , 2 Yet epidemiological studies of adiponectin have shown directionally opposite relationships with adverse outcomes in different populations. Whereas adiponectin is associated with lower incidence of coronary heart disease (CHD) in healthy middle-aged cohorts, 3, 4 it has been linked to higher mortality in groups with prevalent cardiovascular disease (CVD), 5 heart failure (HF), 6 or older age. [7] [8] [9] These contrasting associations, known as the "adiponectin paradox," remain a major puzzle in the field. 10 While the basis for the paradox remains uncertain, the influence of prevalent CVD, and particularly HF, has come to be increasingly appreciated. The observation that adiponectin is absent from the normal vascular wall but detectable at high levels following vascular injury has led to the concept that increased adiponectin concentrations may represent a response to, and hence a marker of, more severe underlying atherosclerosis. 2 In turn, recognition that natriuretic peptides stimulate adiponectin secretion provides a mechanism linking elevated adiponectin levels to more pronounced cardiac dysfunction and a poorer prognosis.
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Previous work from our group suggested a U-shaped association between total adiponectin and mortality among long-term survivors of the Cardiovascular Health Study (CHS), 12 providing a potential path to reconciling the opposite associations. We have since expanded measurement of total adiponectin to a majority of the CHS cohort, and added adiponectin's reportedly more metabolically active high-molecular-weight (HMW) fraction. 13 Here we parlayed such large-scale measurements to better characterize the shape of These contrasting associations, known as the "adiponectin paradox," rema ma ain n n a m m maj aj ajor or or puzzle in the field. 10 While the basis for the paradox remains uncertain, the influence of pr rev ev val al ale en ent t t CV CV CVD, D a a an nd nd particularly HF, has come to to to b be e increasingly y a app pre re ec ci ciat a ed. The observation h h hat t t a adiponect tin in is s ab ab bs s sen nt nt f f fro ro rom m m th the e e n no norm rm rmal v v vas s scular ar wa al all l l bu bu ut de de d te te ec ct tab able le le a at t hi hi igh gh gh l lev ev vel el ls s s fo fo foll l low ow owin in ing g va vasc sc scul ul ular ar a i inj nj njur ur u y y h h has s s le led d d to to o t the e c con on once ce cep pt pt t t tha ha at t t in in incr r rea ea e s se ed d d ad d dip p pon on onec ec cti ti tin n co o onc nc n e en entr tr rat atio io ions ns ns m m may ay ay re e epr re rese se ent nt a a esponse to, , a and nd nd h h hen en ence ce e a a a m m mar ar arke ke k r r r of of o , , mo mo more re re s s sev ev ever er ere e e un un unde de d rl lyi yi ying ng ng a a ath th ther er eros s scl cl cler er eros os osis is is. . . 2 2 2 I I In n n tu tu turn rn rn, , , re r cognition n n adiponectin's associations with all-cause and cardiovascular mortality, and test the hypothesis that these relationships would differ in subgroups defined by prevalent CVD, HF, and atrial fibrillation (AF) status.
Methods

Study Population
CHS is a longitudinal investigation of determinants of CVD in older adults. 14 Participants were 65 years old and residing in the community. They were identified from Medicare eligibility lists and recruited from four field centers in the United States. 14 An original cohort (n=5,201) was enrolled in 1989-90, followed in 1992-93 by an African-American cohort (n=687). As previously described, participants underwent health evaluations at site clinics according to standardized protocols. 14, 15 Of the 5,553 subjects who completed the 1992-93 examination (baseline for this analysis), 838 did not have samples for adiponectin measurement, and 30 had missing information on covariates, leaving 4,685 eligible individuals.
Definition of Covariates
Hypertension was defined by blood pressure 140/90 mm Hg, or self-report and antihypertensive therapy. Diabetes was defined by fasting glucose 126 mg/dl or glucose-lowering treatment.
Anthropometry was performed in standardized fashion. 16 Subclinical CVD was defined as reported previously. 17 Laboratory measurements on fasting blood samples have been described. [18] [19] [20] Homeostasis model assessment of insulin resistance (HOMA-IR), 21 and estimated glomerular filtration rate (eGFR) 22 were calculated using standard approaches.
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The shapes of the associations of total and HMW adiponectin with all-cause and cardiovascular mortality were examined in Cox models using penalized cubic splines. 26 Nonlinearity of these associations was tested with a likelihood ratio test. 26 Based on the strength of non-linearity and the overall shape of the association, we chose to summarize the dominant linear features using two linear splines for Group 1, and a single linear term for Groups 2 and 3.
The use of linear splines for Group 1 has the advantage of allowing assessment of effect modification by relevant covariates, and of direct comparability with findings in Groups 2 and 3.
To further characterize the non-linear relationship of adiponectin with mortality in Group 1, we also report hazard ratios at specific points along the cubic spline; these do not represent division of the data into quantiles but instead show how the hazard function changes across the data. The proportional hazards assumption was confirmed using Schoenfeld's goodness-of-fit procedures.
To determine the independent associations of total and HMW adiponectin with fatal events, we examined the effect of adjusting for potential confounders, or covariates related to both adiponectin levels and outcome but not deemed to be on the causal pathway between the two. We developed sequential multivariable models, initially adjusting for age, sex and race, and subsequently for additional confounding variables, defined as candidate covariates that altered the risk estimate for adiponectin by 10%. Candidate confounding variables included study center; socioeconomic factors; anthropometry; lifestyle habits; blood pressure; antihypertensive or antithrombotic treatment; estrogen therapy; self-reported health status; and eGFR, serum albumin, and N-terminal pro-brain-type natriuretic peptide (NT-proBNP). Assessment of the independent association of adiponectin with mortality was based on the adjusted risk estimates accounting for the aggregate of confounding.
To explore the associations further, we next undertook adjustment for putative mediators, of the data into quantiles but instead show how the hazard function changes acro os s ss t t the he e d d dat at ata. a. a. T Th he proportional hazards assumption was confirmed using Schoenfeld's goodness-of-fit procedures.
To To To d d det et e er rmi mi min ne the independent association on ns s o o of total and HMW M M a a adi di dipo p nectin with fatal ev ven n ents, we exa am m min n ned d d th t t e e e ef ef effe fe fect ct ct o of f f ad ad dju ju ust ting fo o or po o ote e enti ia ial l l co co onf nf fou ound nd nder rs, s or r co co ova va ari riat at tes es e r rel el elat t ted ed ed t t to bo oth th th a a adi di d po po pone ne nect ctin in n le ev evel el ls an an a d d o ou outc tc tco o ome me m b b but ut t n n not ot ot d d dee ee e me me med d t to to b b be e e on on n t t the he e c c cau au ausa sa al pa pa p th th thw wa way y y be be betw w wee e en n th th he wo. We deve ve elo lo lope pe ped d d se se sequ qu quen n nti ti t al al a m m mul ul u ti ti iva va v ri ri riab ab ble le e m m mod od odel el ls, s, , i ini ni iti ti tial al ally ly y a a adj dj djus usti ti ting ng ng f f for or or a a age ge e, , , se se sex x x an an a d race, and d d or factors potentially in the causal pathway between adiponectin and clinical events. These consisted of glycemic, lipid, and inflammatory risk factors, as well as prevalent subclinical CVD, which are favorably influenced by adiponectin in laboratory studies, and could confer a protective association with CVD outcomes. Although adjustment for causal intermediates can introduce bias, 27 we decided to proceed with such adjustment not to formally quantitate direct, as distinct from indirect, effects, but to gain a general insight into the impact of these intermediate factors on the observed confounder-adjusted associations. These analyses were further justified by the complex, and still incompletely defined, biology of adiponectin, which leaves open the possibility that these proposed intermediates could also act as confounders. 28 To assess for interactions of adiponectin with key covariates, appropriate cross-product terms were assessed by the likelihood ratio test. We did not examine total and HMW adiponectin jointly in multivariable models, because the two measures were very highly correlated (r=0.94).
Last, we conducted sensitivity analyses restricting or stratifying the cohort by selected clinical features or length of follow-up.
All analyses were performed with STATA, version 11.0 (College Station, TX), or R version 2.13.0 (http://www.r-project.org). We first tested whether the association of total adiponectin with mortality was similar across the n all or most subgroups. All or most subgroups showed higher concentrations of of f tot ot otal al l adiponectin in women, especially those taking estrogen replacement therapy, non-blacks, and Ca Cali li lifo fo for rn rnia ia ia a a and nd n M M Mar ar aryl y and, but exhibited lower co o onc n n e e entrations in pa pa art r ic cip ip pa an ants with diabetes, and h h hos s se e receivin ng g a an ant tihy hy hype pe ert rt rte en ensi si siv ve ve t t tre re reat at a me me ment ( (pa pa artic cul ul larly ly y, , , be beta ta-b -blo lo oc ck ker e s) s) s) a a and nd l l lip ip pid id-l -l -low ow wer er rin n ng g h her er erap ap apy. y. y. H Hig ig ighe h her r co co conc nce en ent tr trat atio on ns n o o of f f to to tota tal l l ad ad adip ip ipon on onec ec e ti ti in n we we ere e e a a al ls lso o o pr pr p e es esen en ent t am am amon ong g g pa pa part rtic ic ici ip ipan an nts s s o on n n aspirin in Gro ro oup up up 3 3 3, , , an an a d d d in i t t tho ho hose se e r r rec ec e ei ei e vi i ing ng ng a a ang ng ngio io iote te en n nsi si in-n n co co conv nv nver er e ti ti ting ng ng-e e enz nz nzym ym yme e e in in inhi hi ibi bi bito to tors rs r o or free of 3 Groups (i.e., whether significant interaction existed by prevalent CVD and/or HF/AF). Such testing was significant for both all-cause and cardiovascular mortality (p=0.009 and p=0.034, respectively). This validated our decision to stratify by prevalent cardiovascular status in all analyses. Figure 1A shows cubic spline plots depicting the relationship between total adiponectin and all-cause mortality after adjustment for potential confounders. The association of total adiponectin with fatal events was significantly non-linear in Group 1, where a roughly U-shaped relationship occurred. By contrast, there was no evidence of a significant non-linear relationship in Group 2 or 3. The same relationships, modeled using linear splines, are presented in Figure   1B . Findings were similar for HMW adiponectin, and for the endpoint of cardiovascular mortality (data not shown).
Results
Baseline Characteristics and Cross-sectional Associations
Group 1
The relationships in Group 1 were such that total adiponectin was inversely associated with allcause and cardiovascular mortality up to approximately its median value, 12.4 mg/L; beyond this concentration, further increases were directly associated with either outcome. Table 2 presents the associations of total adiponectin with fatal outcomes modeled as linear splines below and above the median adiponectin concentration. After adjustment for potential confounders (model 2), every 1-SD (7.9 mg/L) increase in total adiponectin at concentrations below its median was associated with 19% and 37% lower risks of all-cause and cardiovascular death, respectively. Above the median, there were instead 18% and 24% higher risks of all-cause and cardiovascular mortality, respectively, after adjustment for confounders (model 2). Additional adjustment for NT-proBNP (model 3) led to lower risk estimates below the median adiponectin concentration, but did not materially alter the risk estimates above it.
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T The e e re r lationsh hip ips s i i in G G Gro o oup up p 1 1 1 w w wer ere e e s su suc ch h t that t to o otal ad d dipon on onec ect ti t n n n wa wa as in inve ve ers rsel ely y y as a asso soci ci ciat at ated ed d w w wit it ith h h al l ll- Findings from the cubic splines were consistent with the linear-spline results. After adjustment for confounders (model 2), a concentration of total adiponectin at the 10th percentile was associated with a 13% greater risk of all-cause mortality relative to the median concentration, as was a concentration at the 90th percentile. These risk estimates were not meaningfully changed by adjustment for NT-proBNP or subclinical CVD, but adjustment for putative metabolic and inflammatory mediators, particularly diabetes and HOMA-IR, again attenuated the associations below the median.
The observed bidirectional association for total adiponectin tended to be more marked for cardiovascular than for all-cause mortality, with somewhat stronger risk estimates in both the linear-spline ( Table 2 ) and cubic-spline (Table 3 ) models. Corresponding associations for HMW adiponectin were comparable, if generally weaker, than for total adiponectin, as shown in Supplemental Tables 1 and 2 .
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Groups 2 and 3
In Group 2, there were no significant associations for total adiponectin with all-cause and cardiovascular death after adjustment for potential confounders ( Table 2) . With additional adjustment for proposed metabolic and inflammatory mediators, and especially diabetes or HOMA-IR, there was a modest direct association with all-cause mortality, suggesting that the null association in Group 2 may represent an admixture of lower risk from such putative mediators and high risk related to other mechanisms.
Turning to Group 3, we found a significant direct association between total adiponectin and all-cause, but not cardiovascular, mortality after adjustment for confounders. There was, however, strengthening of the associations after additional adjustment for proposed metabolic/inflammatory mediators, which were comparable and significant for both outcomes.
This suggests that such intermediates partly counter the adverse associations of total adiponectin with mortality from other causes. Findings were consistent for HMW adiponectin (Supplemental Table 1 ).
Assessment of Effect-Modification within Subgroups
We next tested whether the adiponectin-mortality associations in the 3 subgroups with distinct cardiovascular profiles differed according to levels of key covariates. We found effect modification by baseline BMI that was significant in Groups 1 and 2, but not Group 3. For Group 1, the interaction of total adiponectin with BMI was significant for all-cause (p=0.016), but not cardiovascular (p=0.17) mortality. As seen in Figure 2 , this interaction was characterized by blunting of total adiponectin's inverse association with fatal events at values below its median concentration for participants in the lowest tertile of BMI. In Group 2, formal tests of interaction with BMI were significant for all-cause mortality (p=0.028) and nearly so for cardiovascular however, strengthening of the associations after additional adjustment for propos os sed ed ed metabolic/inflammatory mediators, which were comparable and significant for both outcomes.
Th his is is s s su ug ugge ge gest st sts s s th hat at at s su uch intermediates partly cou un nt nte er r the adverse a ass s s oc cia ia iati ti tio ons of total adiponectin w with h h mortality y f f fro rom m m ot ot the he er r c ca caus us uses es. Fi Fi Find nd din n ngs we we were c c co on nsis st ste en ent t fo fo or r HM HM HMW W ad ad a ip ipon on one ec ecti tin n n Su Su upp pp pple le l me me ent nt ntal al T T Ta ab able le e 1 1). ). ) Because weight change, poor health, and subclinical HF can influence adiponectin levels, we repeated our analyses after exclusion of participants with fair/poor health status, antecedent weight loss >10 lbs, or elevated NT-proBNP ( 190 pg/mL), 20 with no change in our results.
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Likewise, results were not meaningfully altered when only incident events after 5 years of follow-up were considered to reduce the potential effect of unrecognized morbidity at baseline on adiponectin levels.
Discussion
Principal Findings
To our knowledge, the present study is the largest to date to assess the relationship of total adiponectin with fatal events in older men and women, and the first to do so concurrently for HMW adiponectin. The scale of the current investigation afforded the opportunity to characterize the associations of total and HMW adiponectin with mortality more precisely than has been possible previously, revealing that among community-dwelling elders such associations differ Because weight change, poor health, and subclinical HF can influence adi di ipo po one nect ct ctin in in l l lev ev e e els we repeated our analyses after exclusion of participants with fair/poor health status, antecedent we weig ig ight ht ht l l los os ss s s >1 > > 0 lb lb lbs, s, or elevated NT-proBNP ( 19 19 190 0 pg/mL), 20 wit it th h h no o c c ch ha hange in our results.
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significantly in nature depending on the presence of clinically overt CVD or HF/AF. In particular, we found that the associations of adiponectin with all-cause and cardiovascular mortality became progressively less favorable across subgroups with increasing baseline cardiovascular risk, shifting from a U-shaped relationship for participants free of prevalent clinical CVD, HF and AF after extensive adjustment for potential confounders, to a flat association for participants with prevalent CVD, and to a direct linear association for individuals with prevalent HF or AF. Additional inclusion of metabolic/inflammatory risk factors proposed to be favorably regulated by adiponectin, particularly diabetes and insulin resistance, rendered these associations across subgroups more adverse and similar in shape, eliminating the inverse association in the lower range observed in the first group, suggesting a direct association in the second, and strengthening the direct association in the third.
Previous Studies
Several population-based studies 7-9 of older adults have found higher total adiponectin to be associated with an increased risk of fatal events. Such associations are at odds with favorable metabolic/vascular effects documented for total, and particularly HMW, 13, 29 adiponectin in experimental studies, 1, 2 and with significant inverse associations with incident CHD reported in healthy middle-aged adults. 3, 4 One potential explanation for the paradoxical associations would be a disjunction between levels of HMW and total adiponectin in older people. The current findings refute this premise, as does a previous study which failed to detect a significant association between HMW adiponectin and incident CHD in older women. 30 The direct relationship of total adiponectin with mortality in older adults has been similarly documented in younger cohorts with prevalent CHD 5 or HF, 6 suggesting that increases in adiponectin levels in response to underlying cardiac or vascular dysfunction serve as markers association in the lower range observed in the first group, suggesting a direct asso so oci ci ia atio io ion n n in in in t t th he he econd, and strengthening the direct association in the third.
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S S Sev ve veral popula lati ti tion on on-b b ba as ased ed d s s stu tu tudi di dies es 7-9 7-9 7 o of f ol lder ad d dults s h h hav v ve e fo foun u und d h hi ig gh her e t t tot otal al a a adi di dipo pone ne nect ct ctin in i to o o be be be as sso so soci ci ciat at a ed ed w w wi it ith h a an an i inc ncre reas ased ed r r ris isk k k of of of f fat at tal al l e e eve ve ven n nts ts ts. . Su Su Such ch ass ss sso oc ocia a ati ti t o on ons s s ar ar a e e at t t o odd dd dds s wi with th th f fav v vor r rab abl le le metabolic/va asc sc scul ul u ar ar ar e e eff ff fec ec cts d d doc oc o um um umen en ente te t d d d fo fo for r r to to tota ta tal, l, l, a a and nd nd p par ar arti ti t cu cu cula la larl rl rly y y HM HM HMW, W, W 13 13 13, 29 29 29 a a adi di dipo po pone ne nect c in in of heightened risk in these settings. 2 Indeed, in a middle-aged/older cohort, increased levels of total adiponectin were significantly associated with higher all-cause mortality in age-and sexadjusted analyses among subjects with, but not without, prevalent CVD. 31 By contrast, in a population of older men stratified by prevalent CVD and HF status, increasing tertiles of total adiponectin showed significant direct associations with fatal events after adjustment for potential confounders and intermediates in the subgroup without prevalent CVD/HF and the one with prevalent HF, but not in the subgroup with prevalent CVD and no HF. 8 Previous work in the long-lived CHS All Stars subset showed a non-linear association between total adiponectin (measured in 2005-06) and mortality that was characterized by significantly increased risk starting at levels ~20 mg/L. 12 After additional adjustment for inflammatory markers, however, the relationship became U-shaped, with a significantly lower risk of death for increasing adiponectin levels up to 20 mg/L. 12 The present findings now demonstrate that the association with mortality is in fact U-shaped for elders without clinically overt CVD or HF/AF, but not apparently so for those with prevalent CVD or HF/AF.
Interestingly, a bidirectional association has also been reported between total adiponectin and left ventricular mass index among middle-aged African-Americans free of prevalent CHD. 32 It bears noting that the inflection point selected in CHS All Stars 12 is higher than that of 12.4 mg/L chosen here. This may relate in part to the higher average adiponectin levels observed, consistent with the older age of CHS All-Stars participants, but the immunoassays used in the two studies are also different. Because adiponectin assays have not been standardized, the inflection points presented are not intended to serve as absolute cutpoints for determination of adiponectin-related risk, but instead as guides to the non-linear associations observed.
Potential Explanation for Findings
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The relationship detailed here for participants without prevalent CVD/HF/AF is consistent with the U-shaped association documented in these subjects for total adiponectin and incident CHD and stroke, 33 or with flattening of the inverse association between adiponectin and new-onset diabetes observed in the upper range of concentrations. 34 Taken together, these findings refine understanding of the adiponectin paradox, indicating that within the lower range of the adipokine's distribution in elders, higher levels do indeed confer a lower risk of all-cause, and particularly cardiovascular, mortality, much as they do for incident CHD in younger cohorts.
That these lower mortality risks were attenuated substantially after adjustment for insulin resistance and diabetes accords with the proposition that adiponectin's regulation of these factors largely mediates the adipokine's favorable association with outcomes. 1 At the upper range of concentrations, however, higher levels cease to lower, and instead heighten, the risk of death, an association that is not meaningfully altered by consideration of metabolic and inflammatory intermediates.
Such adverse prognostic implications for higher adiponectin concentrations in the upper range are consistent with the premise that they represent reactive increases to underlying disease processes. 35 That adiponectin may play an important housekeeping function has gained support from findings that the adipokine promotes the phagocytic clearance of such cells by macrophages, forestalling the inflammation that would otherwise result from their unchecked accumulation. 36 Indeed, the high concentrations of adiponectin found in the bloodstream are consistent with such a "mass action" role that goes beyond the adipokine's receptor-mediated hormonal effects.
The hormonal and mass action properties of adiponectin are believed to be of particular importance to the vascular compartment, 2 but the observation that adiponectin was inversely argely mediates the adipokine's favorable association with outcomes. 1 At the up ppe pe per r r ra a ang ng nge e e of of of concentrations, however, higher levels cease to lower, and instead heighten, the risk of death, an as sso so oci ci ciat at atio io ion n n th th that i i is s s n no not meaningfully altered by c con on o s si ideration of me me etabo bo oli li lic c c and inflammatory n nte e erm rmediates.
Su Such ch ch a adv dv ver r rse se p p pro o ogn gnos os sti tic c c im im impl p plic ic cat at tio io ion n ns f f for or o h h hig ig ghe he er ad ad adi ip ipon on onec ec cti ti in n n co co onc c cen entr tr t at at atio ions ns ns i in t th the e e up up ppe e er r ange are cons ns sis is iste te ent nt nt w w wit it th h h th th he e pr pr p em em emis is se e e th th hat at at t the he hey y y re re repr pr pres es esen en nt t t re re eac ac acti ti ive ve ve inc nc ncre re reas as ases es es t t to o un un unde de derl rl rlyi y y ng disease e e Another important factor is the impact of aging-associated weight loss and sarcopenia, which are major determinants of mortality in older adults and are associated with increased adiponectin levels. 17, 37 We were therefore careful to adjust for BMI, and to take antecedent weight loss into account, but these had minimal impact. There was, however, a suggestion of effect-modification by baseline adiposity in Groups 1 and 2, though not in the smallest subgroup, Group 3. For Group 1 in particular, this was marked by disappearance of the inverse associations below the median among participants with BMI's in the lowest tertile, much as occurred in this group overall after adjustment for insulin resistance and diabetes. In the context of multiple comparisons, the nominally significant p values for interaction and the modest effectmodification noted (for BMI as for race-ethnicity) will require independent replication.
Nevertheless, the blunted inverse associations at lower BMI's could reflect lower relevance of the adipokine's salutary metabolic effects in the absence of excess adiposity, and a predominance of deleterious influences on adiponectin levels among older adults more afflicted by wasting and sarcopenia.
Another important factor is the impact of aging-associated weight loss and nd d s s sar a co co c pe pe peni ni nia, a, which are major determinants of mortality in older adults and are associated with increased ad dip ip pon on ne ec ecti ti tin n n le le leve els ls ls. . The latter considerations also apply to Group 3, and likely explain the similarity of its cubic spline plot to that for the lowest BMI tertile of Group 1, since wasting and sarcopenia are as much hallmarks of the HF syndrome as of aging-associated decline. In fact, it has been documented that among patients with mild-moderate HF, skeletal-muscle wasting is associated with reduced expression of the AdipoR1 receptor and accompanying up-regulation of adiponectin production, attesting to the presence of adiponectin resistance. 38 Whether elevated adiponectin levels in HF (or aging-related sarcopenia) reflect a sizable contribution from skeletal muscle production is uncertain. But in this subgroup with the worst overall prognosis, as in older adults with wasting and lower body weights, dysfunctional homeostatic processes are at their peak. In this context, a compensatory rise in adiponectin levels would be most expected, and its direct link to mortality more apparent after factoring in the adipokine's favorable relationships with metabolic and inflammatory factors. It is also possible, however, that such adiponectin increases could themselves be harmful, either through undesirable catabolic effects in the setting of aging-or HF-associated sarcopenia, or other actions. Further research is necessary to define the underlying mechanisms.
Limitations
Because adiponectin measurements were available only for a healthier subset of CHS participants, the current findings do not necessarily apply to higher-risk older cohorts. Despite counting on a larger number of endpoints than prior investigations, the power to define the shape of adiponectin's relationship with mortality was limited in the subgroups with prevalent CVD and prevalent HF/AF. Further detailing of these associations among elders with clinically overt cardiovascular disorders will require larger samples. In addition, the lack of skeletal muscle mass determinations precluded direct assessment of sarcopenia, whose role in adiponectin-associated peak. In this context, a compensatory rise in adiponectin levels would be most ex ex xpe pe ec cted ed ed, , , an an and d d it its direct link to mortality more apparent after factoring in the ad a ipokine's favorable relationships wi with th h m m m t et etab ab abo ol oli ic a a and nd nd inflammatory factors. It is al l lso so s p possible, how wev ev e er r, , th th tha at such adiponectin n ncr r rea e ses coul ld d d t th t e em ems se elv lv ves es es b b be e e ha harm rm rmfu ful l, e eith he er r thro o ou u ugh un un nde de esi i ira rabl b ble e ca cata ta abo o oli lic c c e ef effe fect ct cts in in in t the he e s se et etti ti ing of f f a a agi gi ging ng ng-or or or H H HF-F-as asso soc ci iat at ted ed sar ar a co co op p pen en enia ia, , or or or o o ot th ther er er a ac c cti io on ns ns. Fu Fu Fur rthe he her r re re r se se sear arch ch ch i is s n ne nece ce c ss ss sar ar ary y t to to d d def efi i ine e e he underlying ng ng m m mec ec echa ha h ni ni nism sm sms. s. s adverse risks warrants further study. Last, our analyses adjusting for metabolic and inflammatory factors must be interpreted with caution owing to the potential for bias in assessing the impact of causal intermediates. 27 The results of such analyses are nonetheless consistent with -but cannot prove -the proposed role of insulin resistance and dysglycemia as key mediators of adiponectin's beneficial association with outcomes.
In conclusion, in this large cohort of community-dwelling older adults, the nature of total and HMW adiponectin's associations with all-cause and cardiovascular mortality differed The e e ad ad dip ip ipok ok o in ine e's di di d s stinc ct ct ass s so oc cia iat ti t o on ons s w wit ith h m mo mort rtal al lit it ity y su sugg gg gges est t t th h hat at fu urt rt rthe he her r r wo work rk rk t to o d d dis se sent ntan an ngl gl g e e th th he un un unde de derl rly y ying ng ng p p pat t tho ho h p ph phy ys ysi io iolo lo ogi gi gica ca al l l m m mech ch chan an ani ism ms ms c c cou ou uld ld p p pr r rov ve ve f f fru ruit it tfu u ul l n the search h fo fo for r r no no nove ve v l l l th th ther r rap ap apeu eu euti ti tic c c ta ta arg rget et e s s s in in in a a agi gi gin n ng g g an an nd d re re rela la ate te ted d d di di diso sord rd rder er ers. s. s n. s ls ls a e e re a as in Table le 2 by guest on April 15, 2017 
